1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Mar 2024
Admin
News Article

HUTCHMED Received sNDA for Savolitinib in China

HUTCHMED Announces Acceptance of Savolitinib sNDA in China for Locally Advanced or Metastatic MET Exon 14 NSCLC, Both in Treatment-Naïve and Previously Treated Patients

Overview

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) has announced today that the China National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application ("sNDA") for savolitinib, aimed at treating adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with mesenchymal epithelial transition factor ("MET") exon 14 skipping alteration, for review. If approved, this will expand the label indication for savolitinib to include treatment-naive patients in China.

Previous Approvals

Savolitinib had previously received conditional approval in China for treating patients with NSCLC with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are ineligible for chemotherapy.
Marketed under the brand name ORPATHYS® by our partner, AstraZeneca, for this patient group, savolitinib stands as the first selective MET inhibitor to gain approval in China.
Given that over a third of the world's lung cancer patients reside in China, with approximately 2-3% of NSCLC cases globally featuring tumors with MET exon 14 skipping alterations, this expanded indication holds significant potential.

Result Data at Conference

Preliminary efficacy and safety data from the first-line cohort of the confirmatory Phase IIIb clinical trial (NCT04923945) were shared during the IASLC World Conference on Lung Cancer (WCLC) in September 2023. Subsequently, final data from the same trial were presented at the European Lung Cancer Congress on March 20, 2024.

Study Results

The findings from this study offer confirmatory evidence supporting savolitinib as a targeted treatment option for both treatment-naïve and previously treated patients with MET exon 14 skipping alteration NSCLC.
In treatment-naïve patients, key indicators such as objective response rate ("ORR"), disease control rate ("DCR"), and median duration of response ("DoR") underscore its efficacy.
For instance, ORR stood at 62.1%, DCR at 92.0%, and median DoR at 12.5 months.
Moreover, the safety profile remained manageable, with no new safety signals observed.

About NSCLC

NSCLC is a prevalent and deadly form of cancer, and identifying actionable mutations like MET exon 14 skipping alterations offers new avenues for targeted therapy.

Savolitinib, as a highly selective MET tyrosine kinase inhibitor, has shown promise in addressing this need.
With its inclusion in the National Reimbursement Drug List (NRDL) for NSCLC treatment and ongoing clinical development for various tumor types, including lung, kidney, and gastric cancers, savolitinib continues to advance as a crucial asset in the fight against cancer.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!